Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Study: Industry-Sponsored Meals Increase Physician Prescribing Patterns of Brand Name Drugs

By Meg Snyder | June 22, 2016

Doctors receiving an industry-sponsored meal prescribe brand-name drugs at significantly higher rates to Medicare patients.

Not only is the way to our hearts through our stomach, but it is also the key to getting physicians to prescribe a brand-name drug to their Medicare patients, according to a study published in JAMA Internal Medicine.

Every pharmaceutical company—once their drug has made it through clinical trials and is available commercially—is eager to get their drugs into the hands of patients who could benefit from these medications. And what stands between these drugs and the patients? Their physicians. 

Researchers investigated the likeliness for physicians to prescribe four on-patent drugs from four different drug classes (all of which are competing with generic medicines in the same class):

  1. AstraZeneca’s Crestor: Statins
  2. Forest Laboratories’ Bystolic: Beta blockers
  3. Daiichi Sankyo’s Benicar: ACE inhibitors and angiotensin receptor blockers
  4. Pfizer’s Pristiq: SSRI and SNRI antidepressants

They pulled their data from the U.S. Open Payments database and matched it with Medicare Part D prescribing information on approximately 279,700 doctors. Rather than speaking fees or research payments, researchers focused on meals.

Researchers found that physicians who received industry-sponsored meals had an “increased rate of prescribing the brand-name medication that was being promoted.”

According to the study findings:

As compared with the receipt of no industry-sponsored meals, we found that receipt of a single industry-sponsored meal, with a mean value of less than $20, was associated with prescription of the promoted brand-name drug at significantly higher rates to Medicare beneficiaries. . . . Furthermore, the relationship was dose dependent, with additional meals and costlier meals associated with greater increases in prescribing of the promoted drug. Our findings were consistent across 4 brand-name drugs . . . 

It is rather incredible to read the study results and note that a mean of 742.2 drugs were prescribed for physicians with full bellies (as compared with 470.1 prescriptions among those who didn’t receive meals). 

Researchers also found that the pricier the meal, the greater the prescription of drugs. That is, for all except Pfizer’s Pristiq. 

Other studies have “analyzed script numbers for doctors receiving pharma payments—and found that higher payments are linked to bigger script numbers—but this is the first to zero in on meals,” according to a report on Fierce Pharma. 

Regardless of whether or not you plan to treat your circle of physician friends to a nice meal when your drug is given the stamp of approval, researchers and industry experts are calling for a new transparency effort to combat this partiality.

According to JAMA Internal Medicine:

Our findings support the importance of ongoing transparency efforts in the United States and Europe. Although voluntary guidelines from the American Medical Association and Pharmaceutical Research and Manufacturers of America allow meals and gifts to physicians of up to $100 in value, our findings indicate that even payments of less than $20 are associated with different prescribing patterns. Small payments and meals should continue to be monitored in the United States and should be incorporated into the European pharmaceutical industry’s recent transparency initiative, which requires drug companies to publicly report payments to physicians with the exception of food and drinks.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

vaccine vial
How end-to-end visibility and machine learning can safeguard the vaccine supply chain
Johnson & Johnson
Johnson & Johnson COVID-19 vaccine shipments plunge
Emergent Biosolutions
Emergent reportedly had serious problems at Baltimore vaccine plant
Canadian flag Canada Sanofi influenza vaccine
Sanofi to spend nearly $700M on new flu vaccine plant in Canada

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards